The fact that the SEC, in connection with that industry review, had requested Wilshire change its disclosure practices regarding conflicts of interest also was not sufficient cause for concern by the PBGC.
Before the change in administrations, the National Institutes of Health (NIH) requested a legal ruling about whether funding of research involving embryonic stem cells would violate the ban.
Brown noted that he had requested his staff at the Bureau of Export Administration to come up with strategies to change the "perception" that Commerce was playing a "secondary role" to the Departments of State and Defense on export controls.